Catalyst Wire Dossier Catalyst Wire Dossier

Zanubrutinib (BGB-3111)

zanubrutinib · BeiGene
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Zanubrutinib (BGB-3111), covering 2022-03-03 to 2022-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma [Phase 2]

See pricing